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ABSTRACT
Background
Noroviruses are the leading cause of viral acute gastroenteritis in humans, noted for causing
epidemic outbreaks in communities, the military, cruise ships, hospitals, and assisted living
communities. The evolutionary mechanisms governing the persistence and emergence of new
norovirus strains in human populations are unknown. Primarily organized by sequence
homology into two major human genogroups defined by multiple genoclusters, the majority
of norovirus outbreaks are caused by viruses from the GII.4 genocluster, which was first
recognized as the major epidemic strain in the mid-1990s. Previous studies by our laboratory and
others indicate that some noroviruses readily infect individuals who carry a gene encoding a
functional alpha-1,2-fucosyltransferase (FUT2) and are designated ‘‘secretor-positive’’ to indicate
that they express ABH histo-blood group antigens (HBGAs), a highly heterogeneous group of
related carbohydrates on mucosal surfaces. Individuals with defects in the FUT2 gene are termed
secretor-negative, do not express the appropriate HBGA necessary for docking, and are resistant
to Norwalk infection. These data argue that FUT2 and other genes encoding enzymes that
regulate processing of the HBGA carbohydrates function as susceptibility alleles. However,
secretor-negative individuals can be infected with other norovirus strains, and reinfection with
the GII.4 strains is common in human populations. In this article, we analyze molecular
mechanismsgoverningGII.4 epidemiology,susceptibility,andpersistenceinhumanpopulations.
Methods and Findings
Phylogenetic analyses of the GII.4 capsid sequences suggested an epochal evolution over the
last 20 y with periods of stasis followed by rapid evolution of novel epidemic strains. The
epidemicstrainsshow alinearrelationshipin time,wherebyserial replacementsemerge fromthe
previous cluster. Fivemajor evolutionary clusters wereidentified,andrepresentativeORF2capsid
genes for each cluster were expressed as virus-like particles (VLPs). Using salivary and
carbohydrate-binding assays, we showed that GII.4 VLP-carbohydrate ligand binding patterns
have changed over time and include carbohydrates regulated by the human FUT2 and FUT3
pathways, suggesting that strain sensitivity to human susceptibility alleles will vary. Variation in
surface-exposed residues and in residues that surround the fucose ligand interaction domain
suggests that antigenic drift may promote GII.4 persistence in human populations. Evidence
supporting antigenic drift was obtained by measuring the antigenic relatedness of GII.4 VLPs
using murine and human sera and demonstrating strain-specific serologic and carbohydrate-
binding blockade responses. These data suggest that the GII.4 noroviruses persist by altering
their HBGAcarbohydrate-binding targets over time, whichnotonlyallows forescape fromhighly
penetrant host susceptibility alleles, but simultaneously allows for immune-driven selection in
the receptor-binding region to facilitate escape from protective herd immunity.
Conclusions
Our data suggest that the surface-exposed carbohydrate ligand binding domain in the
norovirus capsid is under heavy immune selection and likely evolves by antigenic drift in the
face of human herd immunity. Variation in the capsid carbohydrate-binding domain is tolerated
because of the large repertoire of similar, yet distinct HBGA carbohydrate receptors available on
mucosal surfaces that could interface with the remodeled architecture of the capsid ligand-
binding pocket. The continuing evolution of new replacement strains suggests that, as with
influenza viruses, vaccines could be targeted that protect against norovirus infections, and that
continued epidemiologic surveillance and reformulations of norovirus vaccines will be essential
in the control of future outbreaks.
The Editors’ Summary of this article follows the references.
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Globally, noroviruses are the second most important cause
of severe viral gastroenteritis in young children, cause 20% of
endemic diarrheal disease in families, cause traveler’s
diarrhea in all ages, and are especially virulent in the elderly,
as evidenced by recent reports of 19 deaths associated with
norovirus acute gastroenteritis in 2006 in long-term care
facilities in the United States [1–4]. In addition to human
costs, norovirus infections cause severe economic losses as a
single 3 mo hospital outbreak may incur expenses that
approach or exceed $650,000 in supplies, staff time off, and
closed beds [5]. Although noroviruses were ﬁrst observed in
1968, the basic principles governing their molecular and
evolutionary epidemiology and persistence in human pop-
ulations are unclear, but are critically important for devising
intervention strategies, therapeutics, and vaccines that could
minimize the high morbidity, occasional mortality, and
extensive economic burdens associated with disease out-
breaks.
Noroviruses are approximately 38 nm iscosahedral viruses
and contain a 7.5 Kb single-stranded, positive-sense RNA
genome that encodes three large open reading frames (ORFs),
including the ORF1 replicase polyprotein and the major and
minor structural ORFs 2 and 3, respectively. These highly
heterogeneous viruses have been genetically grouped into ﬁve
different genogroups (GI–GV), of which the GI and GII
genogroups are further subdivided into more than 25
different genotypes (for example GII.4 is genogroup II
genotype 4) and account for the majority of human cases.
The ORF2 major capsid protein sequence can diverge by as
much as 60% between genogroups and 20%–30% between
genotypes within a genogroup. The majority of norovirus
outbreaks are caused by the GII.4 genotypes, and pandemic
spread was ﬁrst recognized in the mid-1990s [6]. During
1995–1996, strain US95/96 was responsible for about 55% of
the norovirus outbreaks in the US and 85% of the outbreaks
in The Netherlands [7]. Between 2000 and 2004, US95/96 was
replaced by two new GII.4 variants. In the US, Farmington
Hills [8] was ultimately associated with 80% of norovirus
acute gastroenteritis outbreaks [9]. Simultaneously in Europe,
a new GII.4 variant, GII.4b, emerged and caused outbreaks
during the winter, spring, and summer [10–12]. In 2004, the
Hunter GII.4 variant was detected in Australia, Europe, and
Asia [12–14]. This strain was replaced in early 2006 by two
new cocirculating GII.4 variants in the US, Europe, and Asia
[4]. One of these was Sakai, which represents a neoteric GII.4
outbreak strain associated with outbreaks in health-care
facilities in Southeast Asia [15], although strains that cluster
with Sakai have also been identiﬁed in the US and The
Netherlands. The second 2006 outbreak strain was Minerva,
which was identiﬁed in the US and is identical to strains
identiﬁed in The Netherlands [4].
Norwalk virus (NV, a GI.1 virus) readily infects individuals
who have the gene that encodes a functional alpha-1,2
fucosyltransferase (FUT2) enzyme that allows expression of
histo-blood group antigens (HBGAs) on mucosal surfaces and
a secretor-positive phenotype [16]. Individuals who encode
defects in the FUT2 enzyme are secretor-negative, do not
express the HBGAs necessary for docking and perhaps entry,
and are resistant to infection. The association between HBGA
expression and norovirus susceptibility has been conﬁrmed
for NV and certain other GI and GII strains, including GII.4
[17–21]. However, other enzymes may serve as susceptibility
factors as well, since secretor-negative individuals have
antibodies against human noroviruses (although at lower
titers than secretor-positive individuals [16,17,22]), and
develop clinical illness after challenge with Snow Mountain
virus (GII.2) [22]. The evolutionary mechanisms governing the
persistence and epidemic spread of the GII.4 viruses in
human populations are unknown.
Expression of the norovirus ORF2 major capsid protein
produces virus-like particles (VLPs) and the NV x-ray crystal
structure indicates that dimer formation is required to form
the higher-order structure composed of 180 subunits [23].
The monomer has two domains linked by a ﬂexible hinge: the
shell domain (S), which forms the inner core, and the
protruding domain (P), which forms prominent protrusions
extending away from the structure [23] and is subdivided into
two subdomains. These include P1 (residues 226–278 and
406–520) and P2, which is the most surface-exposed region of
the capsid protein (residues 279–405) [23]. P1 structurally
ﬂanks P2.
Mutational analysis of the surface-exposed P2 subdomain
supports its role in HBGA binding [24–26], suggesting that it
contains the determinants of strain speciﬁcity, receptor
binding [23,27–30], and potential neutralizing antibody
recognition sites [26,31]. More recently, the complex struc-
tures of the P domain of a GII.4 virus, VA387, in complex with
HBGA trisaccharide A- and B- antigens, revealed a ligand
interaction site (site 1) in the P2 subdomain where speciﬁc
capsid residues form a strong hydrogen bond network with
the a-fucose group of the trisaccharide [32]. A second
interaction site (site 2) on the VA387 P2 domain was
predicted to stabilize binding and enhance ligand afﬁnity
by weaker long-distance interactions with the galactose ring
(b-gal) of the trisaccharide [32].
In this article, we report the result of our study of the
molecular mechanisms governing the emergence and persis-
tence of novel epidemic norovirus strains in human
populations.
Materials and Methods
Sequences and Sequence Analysis
A total of 167 full-length GII.4 capsid sequences were
downloaded from GenBank, six sequences were obtained
from our collaborators at the CDC, and three were included
from our own in-house collection, for a total of 176 full-
length amino acid and nucleotide capsid sequences (Table
S1). The amino acid sequences were aligned by ClustalX
version 1.83 [33] using the PAM distance matrix and default
parameters (Figure S1). A variety of parameters and
substitution matrices for the alignment were evaluated using
the program TuneClustal version 1.0 (generously provided by
Dr. Barry G. Hall) and the PAM series matrix was determined
to be the most appropriate, with default gap opening and
extension values. The alignment was reﬁned manually, and
211 sites of variation, deﬁned as any site with a quality score
of less than 100, were exported in table format and ordered
by sequence identity, and then by date of isolation. The
sequences were divided into clusters deﬁned as groups of
sequences containing a minimum of 98% sequence identity
with each other, as determined by the BLASTclust program
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tuebingen.mpg.de). Clusters were further divided into sub-
clusters, which were deﬁned as a smaller cluster of sequences
that shared a minimum of ﬁve identical sites that differed
from the main cluster. Each cluster and subcluster was
ordered by year of isolation. The 211 variable sites were
further reﬁned to identify informative sites, such that
columns in the table were removed based on the following
criteria: (1) columns with single amino acid replacements; (2)
columns containing multiple single incongruous amino acid
replacements; (3) columns containing random amino acid
replacements not associated with a geographic lineage or
speciﬁc cluster; and (4) lineage speciﬁc replacements that
were noninformative (Table S2). This reﬁnement reduced the
211 variable sites to 59 informative sites (Table S3). Major
clusters were deﬁned as those that contained a minimum of
ﬁve sequences. One sequence representative of each of the
major clusters was selected and aligned along with VA387,
which was used as a reference strain.
In addition to the amino acid multiple alignment, the
nucleotide sequences were aligned as codons using the
program PAL2NAL [34] which aligned the corresponding
nucleotide sequences based on the amino acid alignment.
Positive Selection Analyses
To determine if positive selection occurred during the
evolution of the GII.4 strains over the past 20 years, ﬁve
codon sequences from each of the ﬁve major clusters were
selected and aligned. The model selection tool of the HyPhy
package [35,36] (http://www.hyphy.org/) was used to determine
that the Tamura-Nei (TrN) model of evolution was the most
appropriate for conducting the analyses, and three different
codon-based maximum likelihood methods were used to
estimate the dN/dS ratio at every codon position in the
alignment to determine if positive selection occurred. These
methods included: (1) single-likelihood ancestor counting
(SLAC), (2) ﬁxed effects likelihood (FEL), and (3) random
effects likelihood (REL).
Recombination Analysis
In addition, the Genetic Algorithms for Recombination
Detection (GARD) and the Single Break-Point (SBP) methods
of the HyPhy package were utilized to determine if
recombination occurred within the capsid sequences. Fur-
ther, the Recombination Identiﬁcation Program (RIP) version
1.9 beta (http://www.hiv.lanl.gov/) was used as an alternative
approach to determine if recombination was a factor in
capsid sequence evolution.
Phylogenetic Analyses
Phylogenetic analyses were conducted using two different
approaches and by three different strategies. In all cases,
amino acid alignments were used to generate trees by both
Bayesian inference (BI) of phylogeny using MrBayes version
3.12 [37] and by two maximum parsimony (MP) [38] methods:
(1) Molecular Evolutionary Genetics Analysis (MEGA) 4.0
package [39] and (2) Phylogenetic Analysis Using Parsimony
(PAUP) version 4.0b10 [40]. For MrBayes, the alignment was
exported in the nexus format, the amino acid substitution
model was set to Dayhoff [41] using the lset command, and
Markov chain Monte Carlo simulation [42–44] was used to
approximate the posterior probabilities of trees with sam-
pling conducted on four chains over 500,000 generations [45].
Trees were sampled every 100 generations, and the 5,001
trees collected were summarized with the sumt command set
to a burn-in of 1,000, which generated a consensus tree using
the 50% majority rule [45]. The burn-in value was determined
using the sump command with an arbitrary burn-in of 250,
which demonstrated that stationarity occurred prior to the
100,000th generation, indicating that a burn-in of 1,000 was
appropriate for the sumt command [45].
For the MP analysis [38] using MEGA 4.0, a bootstrap
consensus tree inferred from 100 replicates was generated to
represent the evolutionary history of the taxa analyzed [46].
Branches corresponding to partitions reproduced in less than
50% bootstrap replicates were collapsed. The percentage of
replicate trees in which the associated taxa clustered together
in the bootstrap test (100 replicates) were shown next to the
branches [46]. The MP tree was obtained using the close-
neighbor-interchange algorithm [47] with search level 3
[46,47] in which the initial trees were obtained with the
random addition of sequences (ten replicates). The trees were
drawn to scale, with branch lengths calculated using the
average pathway method [47] and were displayed in the units
of the number of changes over the whole sequence. All
positions containing gaps and missing data were eliminated
from the dataset.
MP trees were also generated utilizing the tree bisection-
reconnection branch-swapping method under the heuristic
search option of the parsimony program of PAUP 4.0b10 [40].
Since bootstrapping under the heuristic search option of the
parsimony criterion of PAUP 4.0b10 for MP trees composed
of more than 150 taxa is computationally intensive, the
consensus trees from the PAUP 4.0b10 analyses were
compared to the less-robust bootstrapped trees generated
by MEGA 4.0. Only the most relevant P2 alignment was
bootstrapped under PAUP 4.0b10.
In the ﬁrst strategy, all 176 full-length capsid amino acid
sequences were used to generate trees by each method. In the
second strategy, all full-length amino acid sequences were
divided into groups based upon geographic isolation, and
trees were generated by both methods. In the third strategy,
the capsid amino acid sequence of all 176 sequences was
divided into the three structurally deﬁned domains and
subdomains of S, P1, and P2, and trees were generated for
each of these alignments by both methods. All trees generated
were viewed using TreeViewPPC version 1.6.6 [48] or with
tools from the MEGA 4.0 package.
Further, the bootstrapped MP trees generated by MEGA 4.0
for the entire capsid, S, and P1 were compared to trees
generated utilizing the tree bisection-reconnection branch-
swapping method under the heuristic search option of the
parsimony program of PAUP 4.0b10 [40]. For the P2
subdomain, bootstrapped trees were generated and com-
pared using both methods.
In addition, ancestral sequences were generated for
selected nodes using the ANCECON program at the Max
Planck Institute (http://toolkit.tuebingen.mpg.de/ancescon).
Mapping Informative Sites onto the Predicted Structure
The x-ray crystal structure of the P domain of GII.4 virus
VA387 in complex with the B-trisaccharide [32] (Protein Data
Bank [PDB; http://www.rcsb.org/pdb/home/home.do] accession
number 2OBT) was used to generate comparative models of
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[49–51] with default parameters, and Modeller version 8.2
using the automodel class [52,53]. Five models of each were
generated, and the model with the lowest objective function
score was selected for analyses. The PDB ﬁles generated by
these programs were visualized on molecular modeling tools
MacPyMol (DeLano Scientiﬁc) and Chimera [54]. The evolv-
ing sites were mapped onto each model and onto the tertiary
and quaternary structures of the P domain of VA387 in
complex with A and B trisaccharides [32]. Rosetta Design [55]
was used to generate relevant biological units for GII.4–1987
based upon the VA387 biological unit PDB ﬁle (accession no.
2OBT). Brieﬂy, the changes that deﬁne GII.4–1987 were made
on both chains of the VA387 template using the Rosetta
Design Web server (http://RosettaDesign.med.unc.edu/index.
html) with default parameters. In addition, residues within 5
A ˚ of the variable sites were relaxed to allow repacking of side
chains in the presence of the engineered mutations. Ten
models were generated, with all ten predicting nearly
identical structures.
VEE Replicon Particles and Norovirus Virus-Like Particles
Capsid gene constructs for each of the representative
strains were designed and synthesized as reported previously
[56]. Brieﬂy, the ORF2 genes of GII.4–1997 (LV-NC1) [57] and
GII.4–2002 and 2002a were derived from RT-PCR products
from outbreak stool samples collected in 1997, 2002, and 2004
[58], while the ORF2 genes of GII.4–1987, GII.4–2004 and
GII.4–2005 were synthesized commercially by BioBasic
(https://www.biobasic.com/index.php). To create GII.4–1987
D393G, a primer was designed to replace the Asp395 of GII.4–
1987 with Gly395 of GII.4–1997 and the amino acid change
introduced by PCR. All ORF2 constructs were then inserted
directly into the VEE replicon vector for the production of
VEE replicon particles (VRPs) (VRP-GII.4–1987, VRP-GII.4–
1997, VRP-GII.4–2002a, VRP-GII.4–2002, VRP-GII.4–2004,
and VRP-GII.4–2005) [57,59]. The virus-like particles (VLPs)
were expressed in VRP-infected BHK cells, puriﬁed, and
visualized by negative staining EM [57,59].
Carbohydrate Binding Assays
VLP binding to HBGA-phenotyped salivary samples was
determined as reported [57,60], with the exception of the use
of mouse anti-VLP antisera (either strain-speciﬁc or cock-
tails) followed by anti-mouse-alkaline phosphatase (Sigma
A l d r i c h )a n dp N P P( S i g m aA l d r i c h )f o rV L Pb i n d i n g
detection. VLP binding to synthetic HBGAs was determined
using Neutri-avidin coated plates (Pierce) treated with 10 lg/
ml biotinylated carbohydrate (Glycotech and the Consortium
for Functional Glycomics Grant number GM62116) for 1 h
and washed with PBS-0.05% Tween-20 before the addition of
1–2 lg/ml VLP for 1.5 h at 37 8C or room temperature. VLP
binding was detected as described above. Blockade assays
included serum pretreatment of the VLP for 1 h at 37 8Co r
room temperature before addition to the carbohydrate-
bound plate. Assays using mouse antisera for blockade used
rabbit polyclonal anti-GII VLP antisera followed by anti-
rabbit IgG-AP (Sigma) for VLP binding detection. Blockade
titer 50% (BT50) titers were deﬁned as the lowest percentage
of sera tested that blocked 50% of binding (BT50, blockade
titer 50%) compared to levels determined in the absence of
antibody pretreatment. Serum samples that did not reach a
BT50 by the maximum percentage of sera tested were
assigned a BT50 value equal to 23 the maximum percentage
of sera tested for statistical analysis.
Serology
Samples from an archived GII.4 outbreak occurring in 1988
were obtained from the National Calicivirus Laboratory of
the Centers for Diseases Control and Prevention (Atlanta,
Georgia, United States) and are summarized in Table 1. Any
serum pair with a norovirus-positive stool sample or a   4-
fold increase in anti-LV87 or LV97 IgG response between
acute and convalescent samples (seroconversion) was studied
for IgG reactivity and HBGA-VLP blockade across the panel
of VLPs. Mice were immunized with VRP constructs as
described [57]. Geometric mean titers of both human and
murine VLP-reactive serum IgG were measured by ELISA
[16,22,57] using VLP-binding detection methods as described
above. Human and mouse anti-VLP serum IgG was compared
to a puriﬁed IgG of known concentration for quantitation.
Statistical Analysis
The Mann-Whitney two-tailed test (M-W test) was used to
compare the median IgG responses between groups, and
linear regression analysis was used to compare trends of IgG
reactivity across the VLP panel for human serum samples.
The one-way ANOVA was used to compare responses
between murine immunization groups.
Results
Sequence Analysis and Molecular Phylogeny of the GII.4
Capsid
An amino acid multiple alignment of 176 full-length GII.4
capsid sequences was generated (Figure S1) and columns of
heterogeneity were exported as a table, and ordered by time.
The 211 variable sites were reﬁned to 59 informative sites
(Table S2), and six distinct clusters were identiﬁed based
upon sequence identity (Table S3). The ﬁve major evolu-
Table 1. Characteristics of the GII.4 Outbreak Represented by
the Samples Used in This Study
Category Characteristic
Outbreak name 1988
Date April 1988
Location South Dakota
Setting Veterans Affairs Hospital
Transmission mode Person to person
Mean age 64 y
Female 16%
No. stool samples collected 25
No. samples PCR positive
a 5/18
No. samples sequenced
a 1/5
Genocluster
b GII.4 Camberwell
No. serum pairs
a,c 17/25
Stool HBGA binding
a H type 3 (4/4)
a Samples positive/samples tested.
bDetermined by sequence of region C.
cAcute (days 2–5 postexposure) and convalescent (days 20–22 postexposure) serum pairs
stored at  20 8C since collection.
doi:10.1371/journal.pmed.0050031.t001
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outbreak strains (Table S3). These ﬁve clusters include: (1) the
Camberwell cluster, which ranges from 1987–1995; (2) the
Grimsby cluster from 1995 to 2002; (3) the Farmington Hills
cluster from 2002–2004, (4) the Hunter cluster from 2004–
2006, and (5) the Sakai cluster which includes viruses isolated
2004–2006 (Table S3). One representative sequence was
selected from each major cluster, and these were named
according to the date of isolation. For the Camberwell cluster
MD145_12.1987.US (gbjAY032605, GenBank: http://www.
ncbi.nlm.nih.gov/) was selected and named GII.4–1987. For
the Grimsby cluster, an in-house Lordsdale 1997 (LV-NC1)
[57] isolate was used as the representative sequence and was
named GII.4–1997. Two sequences were used, based upon two
in-house isolates, to represent the Farmington Hills clusters,
and these were named GII.4–2002 for the cluster representa-
tive, and GII.4–2002a for a variant that differs by two
replacements, one at position 226 (Pro in GII.4–2002 and
Ser in GII.4–2002a) and one at site 395 (Ala395 in GII.4–2002
and Thr395 in GII.4–2002a). The Hunter cluster representa-
tive is Hunter284E.04O.AU (gbjDQ078794.2, GenBank: http://
www.ncbi.nlm.nih.gov/), and it was named GII.4–2004. The
Sakai.04_179.2005.JP (dbjjAB220922.1, GenBank: http://www.
ncbi.nlm.nih.gov/) sequence was selected as the representative
sequence for the Sakai cluster and was referred to as GII.4–
2005. These sequences were aligned with VA387 as a
reference sequence and informative sites were exported to
a table (Figure 1). In addition, interaction sites identiﬁed in a
recent structural study of the VA387 P domain were included
(Figure 1).
The sixth cluster, named Den Haag, is composed of three
viruses isolated in 2006, and also contains Minerva, one of the
cocirculating GII.4 strains that caused the GII.4 pandemic in
Europe and the United States during the winter of 2006 [4].
The extent of diversity among the clusters of GII.4 viruses is
approximately 2%, with a total sequence identity of 90%
between the earliest cluster, Camberwell, and the extant
clusters Hunter, Sakai, and Den Haag. While variation was
noted in the S, P1, and P2 regions of the capsid; the majority
of heterogeneity occurred within the P2 subdomain (Figure 1;
Table S3). Of the two receptor interaction sites recently
reported, site 1 was strictly conserved in all clusters, while site
2 was highly variable at positions 393 through 395 (VA387
numbering) (Figure 1). Of note, strains occurring after the
Grimsby cluster encoded an inserted amino acid between
positions 393 and 394 of VA387 (Figure 1).
The fact that most amino acid replacements occurred in
the surface-exposed P2 subdomain indicated that the differ-
ent regions of the capsid protein were evolving under
different evolutionary constraints, suggesting that the P2
region may be evolving by positive selection in response to
herd immunity [61,62]. To determine if positive selection
occurred during the evolution between the earliest cluster,
Camberwell, and the extant clusters, ﬁve sequences were
selected from each major cluster (Table S3), the 25 codon
sequences were aligned, and the alignment was analyzed using
HyPhy to detect positive selection by three different methods.
Figure 1. Evolutionary Analysis of Representative GII.4 Strains from 1987 to Present
Five major evolutionary patterns were observed in the mutational profiles of the GII.4 sequences, and these are represented by GII.4–1987, GII.4–1997,
GII.4–2002, GII.4–2004, and GII.4–2005. Yellow, amino acids present in the late 1980s Camberwell cluster (GII.4–1987); red, changes that occurred to
form the Grimsby (GII.4–1997) cluster; blue, changes associated with the Farmington Hills (GII.4–2002) cluster; green, changes specific to the Hunter
cluster (GII.4–2004); and orange, substitutions important for the Sakai cluster (GII.4–2005). A second GII.4–2002a sequence is included, as it encodes a
single amino acid replacement at positively selected position 395 in the P2 subdomain as compared to GII.4–2002. The P2 region is highlighted in dark
blue beneath the amino acids, with the N-terminal and C-terminal flanking regions of heterogeneity noted in black for the S domain and brown for P1.
Lavender sites represent residues that hydrogen bond to the ligand at site 1; framed residues have been predicted to interact in a second stabilization
domain. Amino acids operating under positive selection are marked below the column with a plus sign. Residues that are not colored represent single
amino acid changes that were not seen in other strains in the cluster. Strain VA387 is included for comparison, as it is a Grimsby-like virus with a solved
crystal structure of the P domain. Bold residues represent amino acids that reverted to a residue from a previous cluster.
doi:10.1371/journal.pmed.0050031.g001
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was the maximum number of sequences available for the
smallest major cluster, Camberwell (Table S3). This approach
indicated that ten sites evolved by positive selection; these
included residues at positions 6, 9, 355, 372, 393, 394/395 (site
394 in viruses of the Camberwell and Grimsby clusters and
position 395 of all later clusters), 412, 505, and 534 (Table 2).
Of note, this analysis was repeated three times using different
random selections of ﬁve sequences from each of the ﬁve
major clusters, and in all cases residues 9, 355, 372, 394/395,
505, and 534 were indicated as operating under positive
selection (Table 2).
Origin of Outliers
Five outlier sequences were identiﬁed that did not appear
to be associated with any cluster, and all of these had amino
acid replacement patterns similar to two different clusters in
different regions of the protein, as would be expected in the
event of recombination, which has been reported for several
genogroups of noroviruses [63]. Recombination analyses
using the HyPhy package and RIP identiﬁed a putative
break-point at position 794 of ORF2, and four of the ﬁve
outlier sequences appear to be recombinants based on
analyses performed by both methods (Table 3). These include
Lanzhou/35666/2002/CHN, GA04/2004/US, Richmont/94/US,
and Erfurt/007/00/DE. Further, two additional sequences were
identiﬁed with substantial sequence anomalies, and these
include EmmensE006/NL, which appears to be mosaic (Table
3), and Beijing/CR2905/CHN, which contains multiple unique
replacements and a deletion that may be the result of
sequencing error (Figure S1).
Patterns of Molecular Evolution
Analyses of the BI and MP phylogenetic trees suggested
that GII.4 capsid evolution was complex. Analysis of the full-
length capsid amino acid sequences by these two approaches
identiﬁed similar but not identical trees in which all six
identiﬁed clusters were represented (Figures 2A, 2B, S2–S4).
However, evolutionary patterns from the earliest to the latest
cluster were confounded. While the Camberwell cluster was
predicted to give rise to the Grimsby cluster, all extant
clusters arose from a single last common ancestor (LCA) that
likely evolved from the Grimsby cluster. However, no single
evolutionary pattern was discernible, suggesting a complex
Table 2. Detection of Positive Selection
Codon SLAC dN/dS SLAC p-Value FEL dN/dS FEL p-Value REL dN/dS REL Bayes Factor
6 2.128 0.481 2.294 0.095 0.502 72.757
9
a 3.204 0.33 2.908 0.056 0.632 159.935
355
a 2.128 0.481 1.682 0.138 0.41 48.935
365 3.315 0.298 2.223 0.079 0.626 149.129
372
a 2.128 0.481 1.941 0.117 0.455 58.71
393 1.845 0.516 2.738 0.253 0.127 40.072
395
a 5.422 0.146 4.786 0.015 0.685 231.954
412 2.198 0.451 1.498 0.148 0.38 42.047
505
a 2.15 0.478 2 0.114 0.46 60.32
534
a 4.428 0.198 3.043 0.118 0.466 85.438
A codon alignment was generated using five sequences from each major cluster, and the dN/dS ratio was determined at every codon position in the alignment to determine if positive
selection occurred using: (1) single-likelihood ancestor counting (SLAC), (2) fixed effects likelihood (FEL), and (3) random effects likelihood (REL) methods of the HyPhy package. This table
presents the ten sites that are predicted to be operating under positive selection. dN/dS ratios and p-values are shown for the SLAC and FEL methods, and the Bayes factor is shown for
the REL analysis. p-Value cutoff for SLAC was 0.2, FEL was 0.1, and the minimum Bayes factor value was set at 40. Bold numbers indicate residues that were significant for each method. In
addition, this analysis was repeated three times using random selections of five sequences from each major cluster and the residue positions indicated by a footnote (
a) were predicted to
be operating under positive selection in all cases.
doi:10.1371/journal.pmed.0050031.t002
Table 3. Recombination Detection Analysis
Virus GARD/SBP Break-Point (794) RIP 1.9 Analysis Status
Cluster 1–794 Cluster 795-1620 From: To: To:
Erfurt/007/00/DE Outlier of GR Outlier of CM CM GR FH R
Lanzhou/35666/02/CHN SK Outlier of SK CM FH — R
Richmont/94/US CM Outlier of CM CM GR — R
EmmenE006/02/NL CM Outlier of CM CM/GR CM/GR — M
GA04/2004/US Outlier of FH FH CM FH — R
Genetic Algorithms for Recombination Detection (GARD) and the Single Break Point (SBP) methods of the HyPhy Package were utilized to determine if recombination could explain the
occurrence of the outlier sequences, which did not fall within any identified cluster. These methods predicted that a break-point occurred at position 794 and showed that trees generated
using nucleotides 1–794 and 795-1620 produced different evolutionary relationships of the outliers. Further, the Recombination Identification Program (RIP) version 1.9 beta was used to
determine amino acid sequence similarity by comparing the known clusters to the potential recombinants.
CM, Camberwell; GR, Grimsby; FH, Farmington Hills; M, mosaic; R, recombinant; SK, Sakai.
doi:10.1371/journal.pmed.0050031.t003
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Mechanisms of Norovirus Persistenceevolutionary pattern in ORF2. In addition, there were several
outliers that did not cluster with any speciﬁc group (Figures
2A, 2B, S2–S4).
To rule out the possibility that geographic variation
confounded the overall phylogeny, we employed a second
approach in which the sequences were separated by geo-
graphic region of isolation and analyzed by BI and MP. Four
major groupings were analyzed with sequences derived
speciﬁcally from The Netherlands, the UK, Germany, and
the US. However, sampling biases and lack of sequences over
the course of the 20-y time frame for each region resulted in
trees that for the most part were incomplete, or that provided
inconsistent evolutionary patterns (unpublished data). Only
The Netherlands tree showed a linear-like progression from
the earliest cluster to extant clusters, consistent with a recent
report from that country [62].
Virus proteins contain multiple functional domains, and
protein domains are recognized as the units of molecular
evolution [61]. Not surprisingly, different domains within a
protein may evolve at different rates based on structural and
functional constraints of the speciﬁc domain, potentially
masking informative evolutionary patterns [61]. Analysis of
the sequence variation of the three different domains of the
GII.4 capsid showed that of the 59 informative sites noted
(Table S3), 11 occurred in the S domain (5% of sites; 11/225 S
alterations), 18 occurred in the P1 subdomain (11% of sites;
18/166 P1 alterations), and 30 occurred in the P2 subdomain
(24% of sites; 30/126 P2 alterations), the surface exposed
region of the capsid protein. This observation suggested that
the different domains were evolving under different evolu-
tionary constraints. Therefore, we employed a more sophis-
ticated approach whereby the capsid amino acid sequences
were divided into the three structurally deﬁned domains and
subdomains of S, P1, and P2, and each region was analyzed
separately. Analysis of the phylogeny of S, which is the most
conserved domain, showed only two predominant clusters
represented by the Camberwell-like sequences as one cluster,
while the second cluster was composed of all other sequences
(Figures 3A, 3B, S5–S7). The P1 domain phylogeny indicated a
linear progression from Camberwell to Grimsby to later
strains, but the tree did not resolve the evolution of the later
clusters of Farmington Hills, Hunter, Sakai, and Den Haag,
and more information is necessary to resolve contemporary
patterns (Figures 3C, 3D, S8–S10). Intriguingly, the surface-
exposed P2 domain phylogeny suggests that the P2 region has
evolved in a linear fashion, punctuated by periods of stasis,
over the last 20 y in a pattern similar to inﬂuenza viruses [64].
Both BI and MP conﬁrmed that the evolution of each cluster
was correlated with time, with the Camberwell cluster being
near the root of the tree, and the Grimsby cluster having
origins in the Camberwell cluster (Figures 3E–3G, S11–S13).
Further, the Farmington Hills and all later clusters appeared
to have arisen from the Grimsby cluster. Evolution beyond
the Farmington Hills cluster is less clear, as it appears that a
LCA, which arose from the Grimsby cluster, gave rise to all
four later clusters. However, the Bayesian posterior proba-
bility at this node was only 57/100 (Figure S11), and an MP
(PAUP) bootstrap value was 65/100 (Figure S13), suggesting
that there was not enough information to fully deﬁne this
branching order. Therefore, we computed the predicted
ancestral sequence for this node and compared this sequence
to the Farmington Hills, Hunter, and Sakai cluster sequences.
The LCA sequence was deﬁnitively more Farmington Hills-
like, which implies that the Farmington Hills cluster is
ancestral to the extant clusters (Table S3). This implication
further suggests that the GII.4 viruses evolved in a linear
manner, with each subsequent cluster giving rise to the next
(Figure 1; Table S3) from Camberwell to Farmington Hills.
Although some clusters persisted for 8 y, contemporary
clusters appear to have evolved from subsequent populations
in much shorter intervals (Table S3), characteristic of epochal
evolution. Taken together, these analyses suggest that the P2
region of the GII.4 viruses evolved in a linear direction over
the last 20 y, with intense heterogeneity within the P2 region
of the capsid sequence facilitating the emergence of new
predominant strains.
To further evaluate this hypothesis, homology models of
each of the ﬁve representative sequences were generated
using the VA387 P domain as a template, and these models
Figure 2. Phylogenic Reconstruction of the GII.4 Capsid Sequence
A multiple alignment was generated using 176 full length capsid amino
acid sequences and trees were generated using BI and MP analysis. The
clusters are marked as follows: yellow, sequences from Camberwell
cluster; red, sequences from Grimsby cluster; blue, sequences from the
Farmington Hills cluster; green, sequences from the Hunter cluster;
orange, sequences from the Sakai cluster; and purple, sequences from
the Den Haag cluster. The trees are drawn to similar scales and are
rooted with the earliest Camberwell cluster.
(A) BI predicts that Camberwell gave rise to Grimsby, which gave rise to
an LCA from which Farmington Hills and a LCA for the three extant
clusters evolved independently (for full tree see Figure S2).
(B) The MP bootstrapped tree generated by MEGA 4.0 was similar to the
Bayesian tree with the exception that the Grimsby cluster gave rise to the
Farmington Hills cluster, and a LCA of all extant clusters arose from
Farmington Hills (for full tree see Figure S3). A MP tree generated by
PAUP 4.0b10 predicted similar results (Figure S4).
doi:10.1371/journal.pmed.0050031.g002
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subdomain altered the capsid structure.
Structural Modeling of GII.4 Evolution
Homology models of the P domain of the capsid monomer
of each of the representative viruses were generated, and the
changes that deﬁned the emergence of each cluster were
highlighted on each predicted structure, as well as the VA387
wild-type structure (Figure S14) [32]. The majority of
heterogeneous sites mapped 180 degrees distal to a previously
reported putative receptor-binding domain (RBD) (Figure
S14) [30], with many of the mutations ﬂanking the two
receptor interaction sites identiﬁed recently (Figure S14) [32].
The biological unit for the GII.4 capsid is a dimer, and
dimerization creates two identical RBDs, each of which
contains the two sites shown to be important for receptor
Figure 3. Phylogenic Reconstruction of the GII.4 Shell Domain and P1 and P2 Subdomains
Independent multiple alignments were generated using 176 amino acid sequences divided into the S, P1, and P2 regions of the capsid, and trees were
generated for each alignment using three different methods, with clusters marked as follows: yellow, sequences from Camberwell cluster; red,
sequences from Grimsby cluster; blue, sequences from the Farmington Hills cluster; green, sequences from the Hunter cluster; orange, sequences from
the Sakai cluster; and purple, sequences from the Den Haag cluster. Unmarked branches represent sequences that did not group with any specific
cluster. The trees are drawn to similar scales and are rooted with the earliest Camberwell cluster.
(A) BI of the S domain predicts only two distinct clusters with Camberwell as the first, while everything else groups into a single large cluster (for full tree
see Figure S5).
(B) The MEGA 4.0 MP tree of the S predicted similar results as the Bayesian tree, although there are two nondistinct clusters arising from the LCA derived
from the Camberwell cluster (for full tree see Figure S6). A MP tree generated by PAUP 4.0b10 predicted similar results (Figure S7).
(C) BI of the P1 domain predicted that the Camberwell cluster gave rise to the Grimsby cluster from which the Farmington Hills and all later clusters
emerged, although the extant clusters were not fully resolved (for full tree see Figure S8).
(D) The MEGA 4.0 MP tree of P1 predicted similar results, although it showed that Grimsby gave rise to the Farmington Hills cluster, from which the later
clusters emerged. However, the Den Haag cluster falls within the Farmington Hills cluster (for full tree see Figure S9). An MP tree generated by PAUP
4.0b10 predicted similar results (Figure S10).
(E) BI of the P2 subdomain predicts that Camberwell gave rise to Grimsby, which in turn gave rise to LCAs from which Farmington Hills and the three
extant clusters evolved independently. All six clusters are distinct (for full tree see Figure S11).
(F) The MEGA 4.0 MP bootstrapped tree agreed with the Bayesian tree (for full tree see Figure S12).
(G) The MP bootstrapped tree generated using PAUP 4.0b10 predicted a nearly identical tree as the Bayesian tree (for full tree see Figure S13). The fact
that all three methods generated similar trees with distinct clusters suggests that the P2 subdomain is the most appropriate region with which to
determine phylogeny for the GII.4 noroviruses.
doi:10.1371/journal.pmed.0050031.g003
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Mechanisms of Norovirus Persistencebinding. Many of the sites that evolve differences between the
GII.4 clusters map to regions surrounding both of these
domains (Figure 4). In general, these residues map to the most
distal edge of P2 where they protrude from the surface
(Figure 4).
Evolutionary analyses showed that the fucose ligand bind-
ing residues reported for site 1 [32] were strictly conserved in
the GII.4 viruses, while one amino acid position in interaction
site 2 at position 393 was highly variable among the
representative viruses. Further, many of the P2 sites operat-
ing under positive selection occur near the two interactions
sites, with position 395 being an important residue adjacent
to interaction site 2.
These observations suggest that the heterogeneity most
likely to interfere with receptor binding occurs in or near site
2. In particular, residues at positions 393–395, which change
with each cluster, likely play a distinct role in carbohydrate
binding afﬁnity and/or avidity. Comparison of a structural
model for the GII.4–1987 biological unit predicted by Rosetta
Design, which contained an Asp at position 393, to the VA387
structure (Figure 5A and 5B), which contains Asn at position
393, predicts that this amino acid difference exerts two
profound effects upon interaction site 2. First, an Asp at
position 393 adds negative potential to site 2, which may
inhibit some carbohydrate interactions (compare Figure 5C
and 5D). Second, the side chain of Asp393 is likely repelled by
a conserved Asp at position 391, resulting in subtle remodel-
ing of interaction site 2 (Figure 5C and 5D), which potentially
alters carbohydrate binding. Our model predicts that changes
in interaction site 2 between GII.4–1987 and GII.4–1997
would alter carbohydrate binding and/or speciﬁcity. Thus, we
introduced the Gly393 of GII.4–1997 into the backbone of
GII.4–1987 by PCR mutagenesis, creating GII.4–1987 D393G,
to study the effect of a single amino acid on HBGA
interaction.
To further examine this region, homology models of GII.4–
2002 (Ala395) and GII.4–2002a (Thr395), which differ by two
amino acids at positions 226 (within the P1 domain) and 395
(within the P2), were compared and shown to have a root
mean square distance of 0.201 A ˚ . The two putative structures
were superimposed and the region of the mutation was
characterized (Figure 5E). Mutating Ala395 to Thr remodels
interaction site 2 by increasing the size of the pocket by 1.1 A ˚
(Figure 5E). In addition, this change is predicted to direct the
negative side chain of Asp391 toward the pocket. The change
at position 226 (Pro to Ser) occurs at the bottom of the P1
subdomain where the protruding domain and the shell
domain are connected by the hinge region. This change
occurs within ﬁve residues of one of the dimer interface sites.
Although these changes are subtle, they may have profound
inﬂuences on carbohydrate binding. From these two models,
we hypothesize that microevolution in site 2 alters carbohy-
drate-binding speciﬁcity, and we predict that GII.4–2002 and
GII.4–2002a will have different binding characteristics,
facilitated by a single amino acid difference in the P2
subdomain.
To further characterize the binding characteristics of the
GII.4–2002 viruses as well as the other representative viruses,
the Camberwell GII.4–1987, GII.4–1987 D393G, Grimsby
GII.4–1997, Farmington Hills GII.4 2002 and 2002a, Hunter
GII.4–2004, and Sakai GII.4–2005 ORF 2 sequences were
inserted directly into the VEE replicon vector and all seven
replicons produced abundant 30–40 nm VLPs following
visualization by negative strain EM techniques (Figure S15)
[65–67].
Carbohydrate Binding Profiles of VLPs
GII2.4–1987, GII.4–1997 and GII.4–2002/2002a demonstra-
ted binding to secretor-positive saliva from individuals of
blood types O, A, and B [60], although binding of GII.4–2002a
Figure 4. Variation Mapped to the VA387 Dimer
Capsid dimerization creates two identical RBD that have been shown to bind to carbohydrate receptors. Each domain contains two sites that facilitate
binding, with site 1 directly binding the a-fucose of B-trimer, shown in RBD#1 in this depiction. Interaction site 2 likely governs specificity, as it provides
weak, long-distance interactions to the b-gal group of the B-antigen. Purple, site 1; pink, site 2; yellow, sites that have changed over 20 years of
evolution; gray, chain A monomer; blue, chain B monomer; green, B-trimer carbohydrate.
doi:10.1371/journal.pmed.0050031.g004
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Mechanisms of Norovirus Persistencewas temperature dependent (Figure 6). These data are
consistent with previously published salivary binding data
for VLPs from Grimsby strains isolated in 1997 and 1998
[57,68]. GII.4–2002a also bound weakly to some secretor-
negative saliva at 37 8C, suggesting that this strain may bind
through the Lewis antigens. In contrast, GII.4–2004 and
GII.4–2005 strains bound only weakly (23 background) to
secretor-positive, blood type B saliva at room temperature.
Since saliva is a complex biological ﬂuid containing many
carbohydrates in varying amounts depending on both the
Figure 5. Subtle Changes in Interaction Site 2 May Govern HBGA Carbohydrate Binding
(A) Two identical RBDs are formed upon dimerization of two capsid proteins (gray, chain A; black, chain B), with each RBD containing two sites
important for HBGA carbohydrate binding. Site 1 (cyan) directly interacts with the ligand, while site 2 (purple) provides weak, long-range interactions
that may regulate receptor specificity.
(B) In VA387, B-trimer (yellow) binds to site 1 by a strong hydrogen bond network.
(C and D) Electrostatic differences between RBDs of VA387 (C) and Rosetta-predicted RBD of GII.4–1987 (D) show that changing an Asp at 393 present in
GII.4–1987 to Asn393 found in the GII.4–1997 cluster significantly alters interaction site 2. Repulsion between Asp393 and a conserved Asp391 forces
the side chain of Asp393 away from the pocket. These alterations likely lead to differences in binding between GII.4–1987 and the GII.4–1997 cluster.
(E) Molecular remodeling by mutation in GII.4–2002 cluster. Homology models for the P domain of GII.4–2002 and GII.4–2002a were generated with
Modeller using the coordinates from PDB accession number 2OBT (in VA387 from cluster GII.4–1997), and the structures were superimposed upon one
another and analyzed for differences. The predicted structures had an RMSD of 0.201 A ˚, with the only change in the structures occurring at position 395,
where GII.4–2002 has an Ala residue and GII.4–2002a encodes a Thr. The addition of Thr at position 395 remodels interaction site 2, increasing the
pocket by 1.111 A ˚. We predict that this subtle change in site 2 will be sufficient to alter HBGA binding.
doi:10.1371/journal.pmed.0050031.g005
PLoS Medicine | www.plosmedicine.org February 2008 | Volume 5 | Issue 2 | e31 0278
Mechanisms of Norovirus Persistencedonor’s genetics and sample integrity, this assay cannot
positively identify speciﬁc carbohydrate binding partners or
identify subtle differential binding patterns within the GII.4
VLP panel [69]. However, in agreement with salivary binding
assays, synthetic HBGA (Figure S16) binding assays revealed
three patterns of carbohydrate binding for the six VLPs
(Figures 7 and S17). Although tested, none of the VLPs bound
to any of the core chain precursor molecules (unpublished
data). The ﬁrst pattern exhibited by GII.4–1987, GII.4–1997,
and GII.4–2002 utilized known FUT2-dependent HBGAs.
GII.4–1987 VLPs bound strongly to H type 3 and less well to
Le
y; GII.4–1997 bound H type 3, but also bound efﬁciently to
Le
y; and A and B and GII.4–2002 bound to Le
y and less
efﬁciently to H type 3 and B. The second pattern exhibited by
GII.4–2002a utilized the Lewis enzyme products Le
a and Le
x
as well as the FUT2-dependent A antigen. GII.4–2002a is the
ﬁrst GII.4 strain reported to bind FUT2-independent
products, indicating a possible pathway for infection of
secretor-negative individuals. GII.4–2004 and GII.4–2005 did
not bind strongly to any of the carbohydrates tested (Figure
7), depicting the third binding pattern. It was particularly
interesting that GII.4–1987 D393G had an intermediate
binding phenotype between GII.4–1987 and GII.4–1997.
Replacement of GII.4–1987 Asp393 with GII.4–1997 Gly393
resulted in the addition of binding to B antigen to GII.4–1987
but not the ability to bind A antigen, indicating that position
393 is important in determining HBGA binding, but that
other surrounding residues must also play a role. Concordant
with the predicted remodeling of the receptor binding
pocket, these data support the hypothesis that sequence
variation in and around the second carbohydrate-stabilizing
domain of ORF2 alters VLP structure and modulates HBGA
binding patterns within a genotype, resulting in changes in
VLP–carbohydrate ligand binding over time (Figure 7).
Serologic Relationships among the GII.4 VLPs
A st h em o s tp r o m i n e n ts u r f a c ep r o j e c t i o n ,t h eP 2
subdomain may be a major antigenic determinant [23]. Thus,
it is possible that the noted sequence variation across time in
the GII.4 ORF2 protein could alter the afﬁnity of antibodies
to the individual outbreak strains and help explain the
continued prevalence and emergence of new GII.4 strains,
worldwide. Consonant with this idea, modeling of the noted
GII.4 variation indicates substantial changes throughout the
surface exposed P2 domain that would be predicted to alter
the serologic relationships (Figure 4). To test this hypothesis,
stools and sera collected from infected participants from a
1988 human GII.4 outbreak were studied for HBGA binding
and VLP reactivity and blockade. Characteristics of the
outbreak and samples collected from it are described in
Table 1. Taken in 1988, these serum and stool samples were
collected during the emergence phase of the GII.4 strains and
potentially represent a baseline (preglobal spread) immune
response to the future global epidemic strains.
Both acute and convalescent serum samples cross-reacted
with each of the time-ordered VLPs. Figure 8 shows the
percentage of individuals who seroconverted to each VLP
Figure 6. GII.4 VLP-Salivary Binding Patterns
GII.4 VLPs were assayed for ability to bind to saliva samples phenotyped for secretor status (Se) and ABO blood type by ELISA. The mean optical density
is indicated by the line in the box. The upper and lower boundaries of the box represent the maximum and minimum values.
(A) VLP binding at 37 8C.
(B) VLP binding at room temperature.
doi:10.1371/journal.pmed.0050031.g006
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serum samples. While reactivity to GII.4–1987 and GII.4–1997
VLPs was similar (geometric mean fold increase 16.3 and 15.1,
respectively), convalescent sera titers to GII.4–2002 (geo-
metric mean fold increase 13.0, p ¼ 0.02), GII.4–2002a
(geometric mean fold increase 3.1, p , 0.001, M-W test),
GII.4–2004 (geometric mean fold increase 10.1, p , 0.01, M-W
test), and GII.4–2005 (geometric mean fold increase 7.8, p ,
0.01, M-W test) were signiﬁcantly and proportionately
reduced as compared to GII.4–1987 (Figure 8). Comparison
of the IgG titer across VLPs also demonstrated a signiﬁcant
negative trend in reactivity of 1988 outbreak convalescent
sera and VLPs representing strains circulating at later times
(p , 0.001, linear regression analysis). Of note, reactivity to
GII.4–2002a was lower than reactivity to all of the other VLPs.
Intriguingly, GII.4–2002 and 2002a differ at P226S and A395T
only in the ORF2 capsid protein, and yet they vary in
antibody reactivity, suggesting that one or both of these sites
may encompass strong immunodominant epitopes.
To evaluate the extent of IgG cross-reactivity induced by
the 1988 GII.4 infection, ﬁve randomly chosen serum pairs
were assayed for reactivity to NV, a genogroup 1 strain [70].
The IgG titers were less reactive across genogroup [22]
(unpublished data). Substantial changes between the reac-
tivity of acute and convalescent serum pairs to NV VLP were
not detected, none of the ﬁve tested pairs had a   4-fold
increase in anti-NV titer (unpublished data), indicating that
the increased response to all of the GII.4 strains is cluster- or
genogroup-speciﬁc, not a broad-spectrum increase in total
IgG in response to viral infection.
Blockade Titer Varies over Time
Blockade experiments provide a biological measure of the
ability of antisera to block the interaction of a speciﬁc VLP
with a carbohydrate ligand partner, a surrogate assay for
neutralization [57,60], in the absence of a cell culture system
for noroviruses. Figure 9A shows the mean percentage of
control binding of VLP in the presence of sera compared to
the binding of VLP in the absence of antibody pretreatment.
Although the acute serum samples reacted with GII.4–1987,
GII.4–1997, GII.4–2002, and GII.4–2002a in the IgG enzyme
immunoassay, none of the acute samples collected blocked
the VLP–HBGA interactions, even at high serum concen-
trations (unpublished data). However, convalescent serum
collected in 1988 blocked GII.4–1987 and GII.4–1997 inter-
action with H type 3 but was substantially less able to block
GII.4–2002 VLP interaction with Le
y and was completely
unable to block GII.4–2002a interaction with Le
a (Figure 9A).
Figure 7. GII.4 VLP–Carbohydrate Binding Patterns at Room Temperature
VLPs were assayed for ability to bind to synthetic biotinylated HBGA bound to avidin-coated plates. The mean optical density is indicated by the line in
the box. The upper and lower boundaries of the box represent the maximum and minimum values.
(A) VLP binding to core chains including an a-1,2-fucose.
(B) VLP binding to either core chains or H antigens modified with the Lewis antigen.
(C) VLP binding to A or B antigen trimer.
(D) Comparison of binding of GII.4–1987, GII.4–1987 D393G, and GII.4–1997 VLPs to select HBGAs.
doi:10.1371/journal.pmed.0050031.g007
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binding by 50% (BT50) was 0.27% for GII.4–1987 and 0.24%
for GII.4–1997 interaction with H type 3 (Figure 9B). These
titers were signiﬁcantly different from the sera titer (0.52%)
needed to block GII.4–2002-Le
y interaction (p ¼ 0.03, M-W
test) and GII.4–2002a-Le
a interaction (.1%) (p , 0.001, M-W
test), suggesting that the early Camberwell and Grimsby
strains share common possible neutralization epitopes with
each other that are not common to the later Farmington Hills
GII.4 strains.
GII.4–1997 and 2002a VLPs both bind to multiple HBGAs
in vitro. Thus, antibody blockade was compared for GII.4–
1997 binding to B trimer, Le
y, and H type 3, and GII.4–2002a
binding to A trimer and Le
a to determine if the antibody
blockade was effective against additional potential carbohy-
drate binding partners. Convalescent serum samples from the
1988 GII.4 outbreak similarly blocked GII.4–1997 with each of
the potential binding partners (Figure 10), indicating that
binding sites for additional HBGAs are physically close to
each other on the GII.4–1997 VLP. In agreement with
blockade of GII.4–2002a interaction with Le
a, GII.4–2002a
interaction with A trimer was unaffected by the 1988 sera
(Figures 9 and 10).
To test if the blockade antibody generated after GII.4
infection could block a distant norovirus strain interaction
with HBGA, ﬁve randomly selected serum pairs were tested
for blockade of NV-H type 3 binding. There was no difference
in the mean percentage of control binding between acute and
convalescent serum samples (unpublished data).
GII.4 Serologic Relationships Using Murine Sera
Analyzing human serum samples is complicated, as
norovirus exposure histories are unknown and serologic
relationships between strains are not well deﬁned [57],
making it challenging to decode the antigenic relationship
between the time-ordered GII.4 strains in humans. As mice
are not susceptible to human norovirus infection, they
provide a clean background in which to study antigenic
relatedness between unique time-ordered norovirus VLPs.
Therefore, we immunized naı ¨ve mice with VRPs encoding the
variant ORF2 of each of the GII.4 strains and collected sera
for testing IgG cross-reactivity and blockade ability. As seen
with human outbreak sera, antisera from mice immunized
with VRP-GII.4–1987 or GII.4–1997 reacted similarly to
GII.4–1987 and GII.4–1997 VLPs and to a lesser degree to
GII.4–2002, GII.4–2002a, GII.4–2004, and GII.4–2005 VLPs
(ranging from 1.6% to 24% of GII.4–1987 and 0.5% to 8% of
GII.4–1997 homotypic responses for later GII.4 strains, p ,
0.05, one-way ANOVA), indicating that antigenic sites are
maintained more completely in early GII.4 strains while
becoming variable in later emergent strains (Figure 11).
Immunization with VRP-GII.4–2002 or 2002a, GII.4–2004, or
GII.4–2005 elicited a strong homotypic response with weaker
cross-reactivity (ranging from 0.03% to 16% of homotypic
response) to all of the other strains tested (p , 0.01, one-way
ANOVA), although GII.4–2002 had cross-reactivity to GII.4–
1997 that was signiﬁcantly higher than the other cross-
reactive responses (p , 0.05, one-way ANOVA) (Figure 11).
Immunization with any of the GII.4 VRPs did not result in a
substantial antibody response cross-reactive to NV (unpub-
lished data).
Murine cross-reactive IgG data support the trend seen with
human serum samples indicating clear serologic differences
between the early and late GII.4 strains. To further test this
hypothesis, blockade experiments were performed using
mouse sera and BT50 values were compared. Antisera raised
against GII.4–1987 and GII.4–1997 reacted similarly and
effectively blocked both GII.4–1987 and  1997 interactions
with H type 3, and both sera were unable to block GII.4–2002/
2002a interaction with HBGA ligands (BT50 p , 0.01, one-
way ANOVA; Figures 12 and S18). Conversely, antisera raised
against GII.4–2002 or  2002a effectively blocked 2002/2002a
interactions with HBGAs but were signiﬁcantly less able to
block GII.4–1987 (BT50 p , 0.05, one-way ANOVA) and
GII.4–1997 (BT50 p , 0.01, one-way ANOVA) interactions
with H type 3, again suggesting that the earlier strains share
common blocking epitopes not found in the later Farmington
Hills strains. GII.4–1987 and GII.4–1997 interaction with H
type 3 was weakly blocked by sera against GII.4–2004 and
GII.4–2005 (Figures 12 and S18). GII.4–2004 and GII.4–2005
sera efﬁciently blocked GII.4–2002-Le
y interaction but were
signiﬁcantly less able to block GII.4–2002a interaction with
Le
a (BT50 p , 0.01 and p , 0.05, one-way ANOVA,
respectively; Figure 12). In fact, GII.4–2002a-Le
a interaction
was not efﬁciently blocked by any sera except the GII.4–2002/
2002a samples, supporting observations with human sera
Figure 8. Anti-GII.4 VLP IgG Titers
The geometric mean titer of anti-VLP IgG (lg/ml) for acute (dotted bars) and convalescent (shaded bars) serum samples collected from a 1988 GII.4
outbreak and the percentage of individuals who seroconverted to each VLP. The mean titer is indicated by the line in the box. The upper and lower
boundaries of the box represent the maximum and minimum values.
*Significant increase in titer between acute and convalescent samples (p , 0.05, M-W).
^Significant difference between convalescent titers compared to GII.4–1987 (p , 0.05, M-W).
doi:10.1371/journal.pmed.0050031.g008
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Mechanisms of Norovirus Persistence(Figure 12). Our inability to identify carbohydrates that
efﬁciently bound GII.4–2004 and GII.4–2005 precluded the
testing of sera from historic strains to block the binding of
contemporary strains to HBGAs. None of the antisera
generated to the GII.4 panel blocked NV-H type 3 inter-
actions at any of the serum concentrations tested (unpub-
lished data). These data support the hypothesis that not only
does antigenic drift occur in the capsid region of GII.4
norovirus strains over time, but that the variation greatly
inﬂuences the ability of preexisting herd immunity to
neutralize extant strains, based on carbohydrate blockade
assays.
Discussion
In this study we show that GII.4 norovirus evolution is
epochal, with periods of stasis followed by the emergence of
novel epidemic strains that evolve in a linear manner over
time, and we map the antigenic variation onto the surface-
exposed P2 capsid structure. Using a time-ordered panel of
GII.4 VLPs from 1987–2005, we demonstrate that speciﬁc
changes proximal to interaction site 2 regulate carbohydrate
binding patterns, which have changed over the 20 y interval.
Using sera from a human outbreak in 1988 and antisera from
mice, we used ELISAs and an in vitro carbohydrate blockade
as a surrogate neutralization assay to demonstrate that the
noted variation alters the serologic and blockade responses
consistent with a model of antigenic drift. Our data suggest a
model of molecular evolution in which norovirus GII.4 strains
persist by evolving novel carbohydrate-binding domains over
time in response to immune-driven selection and by
antigenic drift in the receptor-binding regions of the P2
subdomain.
Evolution in the norovirus capsid gene is complex, and our
data are in agreement with other recent studies that under-
score the critical importance of using protein structure to
guide molecular phylogenetic analyses based on the hypoth-
esis that protein domains evolve at different rates dependent
on structural and functional constraints and environmental
selective pressures [61]. In our analyses, the shell domain
appears to be evolving by random drift, as only 5% of changes
are informative (i.e., became ﬁxed in the population). To a
limited extent the P1 subdomain, and in particular the P2
subdomain, are evolving at higher evolutionary rates,
consistent with our hypothesis that surface-exposed residues
are evolving in the presence of immune selection. High rates
of evolution in surface-exposed residues have also been
reported in chronological sets of HIV samples within
individual patients [71]. As the majority of the 176 ORF2
sequences included in our study belonged to the Grimsby and
Farmington Hills clusters, the limited sequence information
for contemporary clusters reafﬁrms the critical need for
continued surveillance, the collection of full-length capsid
sequence information, and detailed studies on the ORF2
evolutionary patterns of change noted in 2005 and beyond.
Our phylogenetic and evolutionary analyses of the P2
domain of ORF2 suggest that the GII.4 viruses have evolved
linearly over the last 20 y in a fashion similar to inﬂuenza
viruses, with serial replacements occurring sporadically,
suggesting an epochal evolution in which periods of stasis
are followed by sudden transitions [72,73]. The periods of
stasis are likely the result of entropy barriers that generally
occur in highly degenerate genotype-to-ﬁtness populations in
which many genotypes give rise to the same phenotype
[72,73]. During the evolution of the GII.4 viruses, a long
period of stasis of about 8 y or more has occurred within the
ancestral Camberwell cluster, prior to the emergence of the
epidemic Grimsby cluster. Of note, the majority of informa-
tive sites within the S domain occurred during the emergence
of the Grimsby cluster, and these sites became ﬁxed in the
population. With our analyses, we cannot rule out the
possibility that these changes to S were the key changes
structurally necessary to facilitate the emergence of the GII.4
cluster as the predominant epidemic strain. The Grimsby
cluster endured a shorter period of stasis, after which
subsequence clusters appear to have evolved from the
previous cluster in a linear manner. Later clusters appear
to emerge every 1–2 y from 2002 to present. Although all six
clusters are distinct, there is overlap between some clusters,
and the dates of isolation of some strains that group with
ancestral clusters clearly occur after the emergence of later
clusters. This variation suggests that strains from earlier
clusters may continue to circulate, but likely cause asympto-
matic disease, or persist at low levels in the population prior
to going extinct.
Analyses of the evolutionary proﬁles of the GII.4 viruses
suggest that many of the outlier sequences are recombinant
viruses, consistent with earlier reports by other groups [63].
The recombination break-point is predicted to occur near
Figure 9. Blockade of GII.4 VLPs Binding to HBGA by Outbreak Sera
Convalescent serum samples collected from a GII.4 outbreak in 1988
were assayed for blockade of GII.4–1987 and GII.4–1997-H type 3, GII.4–
2002-Le
y, and GII.4–2002a-Le
a interaction and the mean percentage of
control binding calculated compared to the no-serum control binding
(A). Error bars represent SEM. The floating bar plot (B) shows the mean
percentage of sera needed for BT50 for each VLP. The mean titer is
indicated by the line in the box. The upper and lower boundaries of the
box represent the maximum and minimum values.
*Outbreak sera BT50 responses significantly different from GII.4–1987 (p
, 0.05, M-W)
doi:10.1371/journal.pmed.0050031.g009
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Mechanisms of Norovirus Persistencethe ﬁrst P1/P2 boundary (nucleotide position 794/amino acid
265), suggesting that viable recombination may be restricted
to crossover sites that preserve essential protein domain
function (Table 3). In addition, some sites in the P2 region
appear to revolve between a select subset of amino acid
replacements. These sites include 329, 333, 340, 355, and 365.
We predict that these are important sites of antigenic
variation, but are structurally limited in that they must
maintain a speciﬁc physiochemical property important for
the overall capsid structure or the interaction with carbohy-
drate, or are structurally constrained by entry mechanisms.
Sites of heterogeneity predominantly occurred in the
exposed P2 subdomain in and around the two carbohy-
drate-interaction sites that form the receptor binding pocket
[23,26,32]. Site 2 was the most variable region in our model
and changes in this region affected carbohydrate binding
proﬁles. Our empirical studies suggest that escape from herd
immunity may represent the selective force that drives
antigenic variation within and around the receptor binding
pocket on the surface of the GII.4 P2 domain of ORF2.
Variation within the RBD in ORF2 variants is likely under
strong coselection to maintain recognition of one or more
HBGA carbohydrate receptors for docking and perhaps
entry, allowing the GII.4 noroviruses to persist and simulta-
neously circumvent highly penetrant susceptibility alleles that
are common in human populations. Alternatively, as the
current contemporary strains do not bind any carbohydrates
tested, the receptor binding pocket may evolve to recognize
other fucosylated carbohydrates or proteins for docking.
In inﬂuenza viruses, herd immunity—mediated primarily
by neutralizing IgG antibodies [74]—positively selects for
antigenic variation in hemagglutinin, although the exact
effect of individual mutations on antigenicity is complex.
Mutations may occur in one or more of ﬁve neutralizing
epitopes or in the sialic acid-binding site in the hemagglu-
tinin glycoprotein, thus selecting for replacement strains that
circumvent antibody neutralization [64]. Among noroviruses,
the concept of herd immunity is controversial; early human
challenge studies suggested that strain-speciﬁc, long-term
immunity can be elicited following challenge, as 50% of
volunteers did not become infected after multiple challenges
with NV. However, the same study demonstrated that in some
volunteers only short-term immunity was evident [75,76]. In
more recent studies, we and others have argued that long-
term immunity is possible and that pre-exposure history may
inﬂuence the duration of the protective immune response
against individual strains [16,22,77]. Although early mucosal
IgA [16] and T cell [22] responses may include components of
a long-term protective immune response in uninfected,
challenged volunteers, the role of serum IgG in protective
immunity remains controversial. Norovirus-challenged vol-
unteers or outbreak patients mount strong serum IgG
antibody responses that block carbohydrate–VLP interac-
tions in a genogroup-speciﬁc manner in a surrogate
neutralizing assay potentially representing a component of
a long-term protective immunity [57,60]. However, IgG
antibody levels are usually too low in prechallenge sera, or
in salivary or fecal samples, for assaying by these methods.
Importantly, the years following the emergence of a new
epidemic strain in Europe were characterized by decreased
numbers of outbreaks, speculated to be associated with
increased herd immunity [62,77]. If herd immunity drives
GII.4 norovirus evolution, these data predict that serologic
relationships among temporal GII.4 epidemic strains should
change over time.
Although GII.4–1987 and GII.4–1997 VLPs differed by
seven amino acids, no signiﬁcant differences in antibody
Figure 10. Blockade of Alternative HBGA Ligands by Outbreak Sera
Convalescent serum samples collected from a GII.4 outbreak in 1988
were assayed for blockade of GII.4–1997-H type 3, Le
y, and B-antigen
trimer interaction (A) as well as GII.4–2002a-Le
a and A-antigen trimer
interaction (B) and the mean percentage of control binding calculated
compared to the no-serum control binding. Error bars represent
standard error of the mean. The floating bar plot (C) shows the mean
percentage of sera needed for BT50 for each VLP and alternative HBGA
ligand. The mean titer is indicated by the line in the box. The upper and
lower boundaries of the box represent the maximum and minimum
values.
doi:10.1371/journal.pmed.0050031.g010
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experimentally immunized mice, suggesting that the few
amino acid changes did not signiﬁcantly alter variation
between the two strains during the long period of stasis. We
speculate that pre-1995 Camberwell-like strains typically
produced low-level endemic disease in human populations.
By the mid 1990s, a series of mutations evolved that
promoted epidemic spread of the post-1996 Lordsdale/
Grimsby strains in human populations, perhaps by allowing
for more efﬁcient binding with additional HBGA ligands on
mucosal surfaces, altering the stability of the capsid, or
promoting transmissibility. The epidemic spread of the
GII.4–1997-like strains in human populations may have
subsequently allowed for higher levels of herd immunity
and selected for faster antigenic changes in future strains.
Inﬂuenza viruses show similar trends, in that genetic variation
oftentimes, but not always, tracks with antigenic variation,
because some mutations result in disproportionately large
antigenic changes [78]. However, global serologic responses
between GII.4–1987/1997 and GII.4–2002/2002a demonstra-
ted signiﬁcant antigenic differences, reﬂecting the increased
number of variant residues. Concordant with these ﬁndings,
GII.4–2004 and GII.4–2005 epidemic strains were also
serologically quite distinct from GII.4–1987 and GII.4–1997,
and to a lesser extent distinct from GII.4–2002, but not from
2002a. Thus, epidemic replacement strain ORF2 capsid
sequences were antigenically related yet distinct due to
antigenic drift.
Given the high amount of GII.4 cross-reactivity, it is clear
that one or more highly conserved epitopes deﬁne the
serology of this genocluster. Immunodominant neutralizing
epitopes have been described for a number of viruses,
including West Nile virus [79], HIV-1 [80], and foot-and-
mouth disease virus [81]. Findings with the GII.4–2002 and
 2002a ORF 2 capsid proteins support the possibility that
GII.4 noroviruses may also encode a limited number of strong
immunodominant epitopes. Compared to GII.4–2002, the
GII.4–2002a norovirus ORF2 protein differs by two residues,
deﬁned by changes in P1 (P226S) and P2 (A395T), yet is
antigenically quite distinct from all other strains tested
(Figures 8, 9, 11, and 12). Previous work with foot-and-mouth
disease virus, demonstrated that a single-amino acid change
in an immunodominant epitope resulted in two antigenic
speciﬁcities and a lack of virus cross-neutralization [82].
Although speculative, the noted P2 variation is unlikely to
encode this strong serologic change in GII.4–2002a, as other
time-ordered VLPs encode amino acid changes at this
position as well. Rather, we predict that the alteration in P1
(P226S) might well deﬁne a major immunodominant epitope.
Experiments are in process to test this interesting hypothesis.
On the structural model, the side chain of Ser226 is much
smaller than the Pro side chain and it extends away from the
surface into an open cavity below the dimer interface region.
This change may alter the ﬁnal conformation of the viral
capsid by relaxing the constraints on the hinge movement.
Clearly, detailed structure analyses of the time-ordered GII.4
VLP set will likely prove informative.
All convalescent outbreak sera blocked carbohydrate
binding of GII.4–1987 and GII.4–1997 VLPs but were less
capable of blocking GII.4–2002/2002a binding. Interestingly,
the mouse anti-GII.4–2004 and GII.4–2005 sera more efﬁ-
ciently blocked binding of GII.4–1987 and GII.4–1997 to H
type 3 than GII.4–2002/2002a binding to Le
y and A. Of note,
amino acids at positions 329, 355, and 365 in GII.4–2004 and
GII.4–2005 are the same as GII.4–1987 and GII.4–1997, but
not GII.4–2002/2002a, which implies that these sites may
Figure 11. Murine Antisera Cross-Reactivity to GII.4 VLPs
Mice were immunized by footpad inoculation on days 1 and 21 with 2.5310
6 IU VRPs expressing GII.4–1987, GII.4–1997, GII.4–2002, GII.4–2002a, GII.4–
2004, and GII.4–2005 ORF2 (n¼4 per inoculation group). Antisera were collected on day 35 and analyzed for homotypic and heterotypic IgG responses
to each VLP by ELISA. Antibody titers are represented as geometric mean lg/ml serum IgG. Error bars represent standard error of the mean.
*VLPs with significantly different reactivity within an immunization group responses (p , 0.05, one-way ANOVA).
doi:10.1371/journal.pmed.0050031.g011
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GII.4–2005 sera to GII.4–1987 and GII.4–1997 carbohydrate
binding. These sites may also be important determinants of
antigenic variation within the GII.4 genocluster.
The absence of a robust cell culture model for noroviruses
prevents the development of classical neutralization assays.
However, studies with numerous virus families have indicated
that antibodies that block virus receptor–ligand interactions
provide one mechanism to neutralize virus infectivity [83–85].
Previous studies by our group and others have demonstrated
that noroviruses bind to HBGAs, and that HBGAs are
necessary for infection, since the FUT2 gene is a susceptibility
allele for Norwalk virus infection in vivo [16,19]. Although a
GII.4 human challenge model does not exist, some GII.4
noroviruses have been reported to bind speciﬁcally to H type
3 and to a lesser extent to the A and B carbohydrates,
suggesting usage of HBGAs in infection [57,86]. Further, GII.4
outbreak investigations have established a strong correlation
between a secretor-positive phenotype and symptomatic
infection [21]. However, carbohydrate-binding patterns with-
in a temporal panel of norovirus VLPs have not been
reported until now. Consonant with clear variations in
overall serologic identity among the GII.4 VLP panel, we
have also demonstrated that the GII.4 VLPs display variant
binding patterns to carbohydrates typically regulated by
FUT1 (Le
x,L e
y), FUT2 (H Type 3), FUT3, the Lewis enzyme,
(Le
a,L e
y), and the A and B enzymes. These ﬁndings suggest
that some GII.4 noroviruses not only bind carbohydrates
regulated by the FUT2 susceptibility allele, but also can bind
carbohydrates regulated by FUT1 and FUT3 and the A and B
alleles as well. However, to date, FUT1 expression has not
been demonstrated in the gut mucosa [87]. As fucosyltrans-
ferase enzymes lack tight core chain ﬁdelity in vitro, it is
possible that the FUT2 enzyme, or another fucosyltransferase,
may express typically FUT1-regulated carbohydrates in the
gut, as has been observed in saliva where FUT2 activity
produces both Le
x and Le
y from type 2 core chain [87].
Further, we and others have not seen in vivo evidence of core
chain usage by alternative fucosyltransferases, as FUT2-
negative individuals were completely resistant to NV infec-
tion [16] and more likely to be asymptomatic after GII.4
exposure [21], regardless of the presence of other fucosyl-
transferases. Most surprisingly, the GII.4–2004 and GII.4–
2005 strains did not bind any HBGA carbohydrates or saliva
tested, suggesting that their carbohydrate ligands are either
not represented within the panel of biotinylated HBGA
carbohydrates available for testing, carbohydrate patterns
differ in saliva and in intestinal mucosa, or they utilize non-
HBGA-mediated pathways for entry. Thus, over time, it is
reasonable to predict that noroviruses have the capacity to
utilize the large number of related HBGAs as ligands. The
potential plasticity in the carbohydrate-binding site would
likely accommodate sufﬁcient amounts of antigenic drift to
escape herd immunity, while simultaneously preserving
carbohydrate-binding potential and altering strain suscepti-
bility to the many different human alleles that regulate HBGA
expression.
Fucose ligand binding site 1 was strictly conserved in the
GII.4 viruses, including, paradoxically, extant strains that only
weakly bind saliva and do not bind any carbohydrate tested.
In contrast, the secondary interaction site appears to
facilitate carbohydrate speciﬁcity as binding characteristics
of the time ordered VLP panel varied extensively. In
interaction site 2, positions 390, 391, 392, and 443 were
conserved throughout the GII.4 strains while sites 393, 394,
and 395 were variable. In two instances, binding character-
istics could be directly correlated to residue changes within
this region. First, structural models predicted that carbohy-
drate binding would differ between the Camberwell cluster
and the Grimsby cluster (including VA387), based primarily
upon an Asp-to-Asn change at position 393 in site 2 (Figure
5). In agreement with our hypothesis, binding between GII.4–
1987 and GII.4–1997 was different. The substitution of an Asp
at position 393 was predicted and then empirically demon-
strated to sterically hinder or otherwise alter binding of the
larger trisaccharide moieties of A- and B- antigens, as the
Camberwell representative VLP binds H type 3 and Le
y but
not A or B (Figure 7). In contrast, both GII.4–1997 and VA387
bind H type 3, Le
y, A, and B [57,88]; and they encode Gly and
Asn at the 393 position, respectively. Interestingly, our data
suggest that the primary impact of the mutations that
occurred between the Camberwell and Grimsby clusters led
to an expansion of HBGA usage, as representative strains
GII.4–1987 and GII.4–1997 were indistinguishable antigeni-
Figure 12. Murine Antisera Blockade of GII.4 VLP Binding to HBGAs
Antisera collected from mice immunized against each GII.4 ORF2 were assayed for blockade of GII.4–1987- and GII.4–1997-H type 3, GII.4–2002a-Le
a, and
GII.4–2002-Le
y interaction and the mean percentage of control binding calculated compared to the no-serum control. The floating bar plot shows the
mean percentage of sera needed for BT50 for each antisera and each VLP; the mean titer is indicated by the line in the box. The upper and lower
boundaries of the box represent the maximum and minimum values. Antisera groups that did not block 50% VLP–HBGA binding at the highest serum
concentration tested (5%) were assigned an arbitrary value of 10%.
*VLPs with significantly different BT50 titer compared to the homotypic antisera-VLP BT50 titer (p , 0.05, one-way ANOVA).
doi:10.1371/journal.pmed.0050031.g012
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Mechanisms of Norovirus Persistencecally. In the second case, a Thr at position 395, as exhibited by
GII.4–2002a (Figure 5E) altered the receptor binding pattern
as this mutant bound to Lewis enzyme products, Le
a and Le
x,
as well as the FUT2-dependent product, A antigen. GII.4–
2002a is the ﬁrst GII.4 strain reported to bind FUT2-
independent products, indicating a possible pathway for
infection of secretor-negative individuals. Alanine at this
position facilitates binding of H type 3 in GII.4–2002. These
results are also in agreement with our hypothesis that
microevolution in site 2 alters carbohydrate-binding inter-
actions; more detailed genetic studies should conﬁrm this
hypothesis. Of note, the synthetic HBGAs used in this study
lack the complex structures often found in vivo. Larger
polysaccharide moieties likely play a crucial role in carbohy-
drate afﬁnity and avidity by interacting directly with
interaction site 2.
Taken together, our structural models (Figure 5) suggest
that heterogeneity in the receptor interaction site 2 likely
determines HBGA afﬁnity and avidity, and subtle changes in
this region may govern HBGA speciﬁcity. Tan et al. [30]
demonstrated that binding of VA387 to HBGAs could be
ablated by mutating the Thr at position 338 to Ala. While
Thr338 is not directly involved in ligand binding, it does form
hydrogen bonds to Arg345, which directly hydrogen bonds to
the ligand [23,26,32]. It seems likely that hydrogen bonding
patterns also inﬂuence which ligands the virus can bind.
Subtle changes to residues that form hydrogen bonds with the
primary ligand interaction residues may drastically alter
ligand afﬁnity and avidity. In addition, the length and charge
of the side chain of a given residue likely allosterically
regulates the site by sterically hindering some interactions
(Figure 5). Studies with foot-and-mouth disease virus have
demonstrated that this virus contains a conserved shallow
pocket on its surface that is predisposed to evolve a high
afﬁnity for its heparin sulfate receptor. Mutations remodel
the surface by increasing the positive charge, which results in
an increased afﬁnity for its receptor [89]. Differences in
electrostatic potential may regulate HBGA afﬁnity in GII.4
viruses as well, as the addition of a charge at position 393
alters the surface charge and binding of the GII.4–1987 virus
(Figure 5A–5D). Studies with inﬂuenza virus have shown
broad serologic differences between temporally distinct
strains consistent with a phenotype of antigenic drift and
variation, especially in antigenic sites, receptor-binding sites,
and codons previously identiﬁed as being under positive
selection [64].
Virus recognition of variant carbohydrate receptor moi-
eties is not unprecedented; inﬂuenza viruses recognize
variant sialic acid moieties for infection of aquatic birds
(a2–3 sialic acid) and humans (a2–6 sialic acid), and other
viruses utilize similar mechanisms [90–92]. However, the
recognition speciﬁcities are much more subtle and complex
than originally appreciated. Recently developed glycan
microarray tools have demonstrated that different human
and avian inﬂuenza virus strains bind to different glycan
ligands depending upon downstream fucosylation, sulfation,
and additional sialylation processing patterns, although the
biological signiﬁcance of these interactions are not fully
known [93]. Our data and that of others [62,77] suggest that
antigenic drift in norovirus ORF2s (HBGA antigens) and
perhaps inﬂuenza virus (sialic acid-containing antigens)
hemagglutinin may evolve by similar mechanisms. The
combined ﬂexibility of the ligand-binding pocket and the
wide range of variant, yet related carbohydrate ligands, may
provide the plasticity in both the receptor targets and viral
attachment proteins necessary to allow for extensive anti-
genic drift in the face of herd immunity.
The data presented in this manuscript provide support for
the hypothesis that antigenic drift and receptor switching
may function synergistically to maintain the GII.4 noroviruses
in the presence of human herd immunity. Our data suggest
that strain-speciﬁc protective immunity is possible and that
vaccines and immune prophylaxis must be formulated to
protect against contemporary strains. As shown with inﬂu-
enza viruses, new therapeutic formulations will be necessary.
Moreover, continued norovirus surveillance will be essential
for maintaining vaccine and drug effectiveness.
At this time, it is unclear whether GII.4 noroviruses will
continue to predominate as the major cause of epidemic
gastroenteritis worldwide, or (like inﬂuenza virus) undergo
an antigenic shift to a variant GI or GII genocluster that is
currently circulating at low levels in human populations, or
whether a new strain will be introduced from zoonotic pools.
However, important caveats must be considered when
evaluating this work. While it is clear that the mucosal
compartment has high concentrations of IgG, carbohydrate–
VLP blockade assays use serum IgG, whereas mucosal IgA and
IgG responses may be more important in protective
immunity [16,57]. Unfortunately, mucosal antibody concen-
trations are usually not only insufﬁcient for blockade studies,
but were not obtained during norovirus outbreaks, prevent-
ing the testing of this possibility. In the absence of a robust
cell culture model, blockade studies themselves represent a
surrogate assay for neutralization, and it is possible that
antibodies might neutralize virus infectivity by binding to
regions distinct from the carbohydrate-binding pocket or
even outside of P2 and inhibit other steps in entry, as shown
with West Nile virus, among others [94]. Research is clearly
needed to deﬁne the number and location of the neutralizing
sites in the norovirus particle and the impact of positively
selected mutations on the neutralization phenotype. Struc-
tural studies solving variant carbohydrate-binding character-
istics in the time-ordered VLP set will be imperative for
understanding the role of the secondary sites in receptor
speciﬁcity and binding afﬁnity. Further, the VLPs used in this
study are composed of ORF2 major capsid protein, whereas
native virions would also include one or two copies of the
ORF3 protein [95]. The function of the ORF3 protein is still
unclear, and its effect on virus structure and interaction with
ligands is unknown. Although no examples of norovirus VLP
post-translational modiﬁcations have been reported, any
such modiﬁcations may impact ligand interaction. In this
study VLPs were produced in a mammalian expression
system, thus post-translational modiﬁcations should reﬂect
natural processing. Finally, although HBGAs clearly function
as ligands for Norwalk virus entry, clear evidence that HBGAs
function for GII.4 docking and entry is less robust, but
suggestive, and it is not clear whether differential binding
patterns noted in vitro reﬂect in vivo binding and suscept-
ibility phenotypes [18,21]. In the absence of time-order GII.4
human challenge inocula, it will be difﬁcult to deﬁnitively
prove that contemporary strains circumvent immune re-
sponses to preexisting strains. Additional studies will be
needed to determine whether the evolutionary patterns are
PLoS Medicine | www.plosmedicine.org February 2008 | Volume 5 | Issue 2 | e31 0286
Mechanisms of Norovirus Persistenceunique to the GII.4 noroviruses or represent a general
evolutionary pattern of the norovirus family. Our study,
however, presents a predictive model for future empirical
studies investigating the relationships among antigenic
change, norovirus pathogenesis, vaccine design, and human
disease.
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Figure S14. GII.4 Evolution Modeled on the VA387 Capsid Monomer
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purple, ligand-binding site 1; pink, interaction site 2. Each panel
represents counterclockwise revolutions on the y-axis.
Found at doi:10.1371/journal.pmed.0050031.sg014 (1.7 MB PDF).
Figure S15. Electron Micrograph of GII.4 VLPs
Puriﬁed GII.4 ORF2 VLPs were visualized by negative stain EM.
Found at doi:10.1371/journal.pmed.0050031.sg015 (1.8 MB PDF).
Figure S16. Biosynthetic Pathway of Histo-Blood Group Antigens
HBGA of the intestinal tract are produced by the successive addition
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type 3 (A), and type 2 core chain (B).
Found at doi:10.1371/journal.pmed.0050031.sg016 (25 KB PDF).
Figure S17. GII.4 VLP-Carbohydrate Binding Patterns at 37 8C
VLPs were assayed for ability to bind to synthetic biotinylated HBGAs
bound to avidin-coated plates. The mean optical density is indicated
by the line in the box. The upper and lower boundaries of the box
represent the maximum and minimum values.
(A) VLP binding to core chains including an a-1,2-fucose.
(B) VLP binding to either core chains or H antigens modiﬁed with the
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(C) VLP binding to A- or B-antigen trimer.
Found at doi:10.1371/journal.pmed.0050031.sg017 (24 KB PDF).
Figure S18. Murine Antisera Blockade of GII.4 VLP Binding to
HBGAs
Antisera collected from mice immunized against each GII.4 ORF2
were assayed for blockade of GII.4–1987-H type 3 (A), GII.4–1997-H
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Table S1. 176 Norovirus ORF2 Sequences Used in This Study
Accession numbers beginning with EU are newly sequenced strains
received from CDC.
Found at doi:10.1371/journal.pmed.0050031.st001 (36 KB XLS).
Table S2. Identiﬁcation of Informative Sites
A total of 211 variable sites were reduced to 59 informative sites
based upon four criteria: (1) columns with single amino acid
replacements; (2) columns containing multiple single incongruous
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replacements not associated with a geographic lineage or speciﬁc
cluster; and (4) lineage-speciﬁc replacements that were noninforma-
tive.
Found at doi:10.1371/journal.pmed.0050031.st002 (17 KB XLS).
Table S3. GII.4 Sequences Used in This Study
The 176 sequences used in this study were aligned with ClustalX,
reﬁned as described, and 59 informative sites were exported to an
Excel table, shown here. The sequences were arranged into clusters
based upon at least 98% sequence identity. Clusters were named
according to outbreak strains associated with the cluster, and these
are marked by color and by name in the ‘‘Cluster’’ column. The
Camberwell and Hunter clusters were further divided into subclus-
ters by sequence similarity (at least ﬁve residues in common among
all subcluster, but not cluster, sequences), and all clusters and
subclusters were arranged by date of isolation. Amino acid replace-
ments associated with each cluster are highlighted as follows: yellow,
amino acids derived from the Camberwell cluster (1987–1995); red,
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evolved in the Farmington Hills cluster (2002–2004); green, amino
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CM, Camberwell, DH, Den Haag.
Found at doi:10.1371/journal.pmed.0050031.st003 (356 KB PDF).
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Mechanisms of Norovirus PersistenceEditors’ Summary
Background. Noroviruses are the leading cause of viral gastroenteritis
(stomach flu), the symptoms of which include nausea, vomiting, and
diarrhea. There is no treatment for infection with these highly contagious
viruses. While most people recover within a few days, the very young
and old may experience severe disease. Like influenza, large outbreaks
(epidemics) of norovirus infection occur periodically (often in closed
communities such as cruise ships), and most people have several
norovirus infections during their lifetime. Currently, 100,000–200,000
people are being infected each week in England with a new GII.4 variant.
There are several reasons for this pattern of infection and reinfection.
First, the immune response induced by a norovirus infection is short-
lived in some people, but not all. Second, there are many different
noroviruses. Based on their genomes (genetic blueprints), noroviruses
belong to five ‘‘genogroups,’’ which are further subdivided into
‘‘genotypes.’’ An immune response to one norovirus provides little
protection against noroviruses of other genogroups or genotypes. Third,
like influenza viruses, noroviruses frequently acquire small changes in
their genome. This process is called antigenic drift (antigens are the
molecules on the surface of infectious agents that stimulate the
production of antibodies, proteins that help the immune system
recognize and deal with foreign invaders). Norovirus epidemics occur
when virus variants emerge to which the human population has no
immunity.
Why Was This Study Done? It is unknown exactly how noroviruses
change over time or how they persist in human populations. In addition,
little is known about susceptibility to norovirus infections except that
secretor-positive individuals—people who express ‘‘histoblood group
antigens’’ (HBGAs, a heterogeneous group of sugar molecules by which
noroviruses attach themselves to human cells) on the cells that line their
mouths and guts—are more susceptible than secretor-negative people,
who express these antigens only on red blood cells. Information of this
sort is needed to devise effective intervention strategies, therapies, and
vaccines to reduce the illness and economic costs associated with
norovirus outbreaks. In this study, the researchers investigate the
molecular mechanisms governing the emergence and persistence of
epidemic norovirus strains in human populations by analyzing how GII.4
norovirus strains (the genotype usually associated with epidemics) have
changed over time.
What Did the Researchers Do and Find? The researchers analyzed the
relationships among the sequences of the gene encoding the capsid
protein of GII.4 norovirus strains isolated over the past 20 years. The
capsid protein forms a shell around noroviruses and is involved in their
binding to HBGAs and their recognition by the human immune system.
The researchers found that the virus evolved in fits and starts. That is, for
several years, one cluster of strains was predominant but then new
epidemic strains emerged rapidly from the cluster. In all, the researchers
identified five major evolutionary clusters. They then created ‘‘virus-like
particles’’ (VLPs) using representative capsid genes from each cluster and
showed that these VLPs bound to different HBGAs. Finally they
measured the antigenic relatedness of the different VLPs using human
blood collected during a 1988 GII.4 outbreak. Antibodies in these
samples recognized the VLPs representing early GII.4 strains better than
VLPs representing recent GII.4 strains. The ability of the blood samples to
block the interaction of VLPs with their matching HBGAs showed a
similar pattern.
What Do These Findings Mean? These findings suggest that the part of
the norovirus capsid protein that binds to sugars on host cells is under
heavy immune selection and evolves over time by antigenic drift. They
show that, like influenza viruses, GII.4 viruses evolve through serial
changes in the capsid sequence that occur sporadically after periods of
stability, probably to evade the build up of immunity within the human
population. Variation in this region of the viral genome is possible
because human populations express a great variety of HBGA molecules
so there is always likely to be a subpopulation of people that is
susceptible to the altered virus. Overall, these findings suggest that it
should be possible to develop vaccines to protect against norovirus
infections but, just as with influenza virus, surveillance systems will have
to monitor how the virus is changing and vaccines will need to be
reformulated frequently to provide effective protection against norovirus
outbreaks.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050031.
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